Novartis India

Company snapshot

Novartis India maintains 341 tracked programs across Chronic Spontaneous Urticaria, Asthma, Systemic Lupus Erythematosus, Breast Cancer, Multiple Sclerosis, IgA Nephropathy, Hidradenitis Suppurativa (HS), Carcinoma, Non-Small-Cell Lung, Atherosclerotic cardiovascular disease (ASCVD), Type 2 Diabetes Mellitus, Non-small Cell Lung Cancer, Chronic Obstructive Pulmonary Disease. Momentum score: 30/100

• 53 approved product(s) across US/EU regulatory metadata.
• 341 active pipeline program(s) linked via ClinicalTrials.gov.
• 341 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Novartis India. Not investment advice.

• Congress Jun 22, 2026
  BIO
• Presentation Jun 22, 2026
  Phase III Lp(a)HORIZON study of pelacarsen: top-line results
• Presentation Jun 17, 2026
  Phase 3 Lp(a)HORIZON study results for pelacarsen

• Peer + 0 momentum

  AstraZeneca

  TA overlap score 60

• Peer + 0 momentum

  Regeneron UK

  TA overlap score 50

• Peer + 0 momentum

  Sanofi-Aventis U.S

  TA overlap score 50

• Peer + 0 momentum

  Merck KGaA, Darmstadt

  TA overlap score 42.6

• Peer + 0 momentum

  GSK Glaxo Smith

  TA overlap score 40

• Peer + 0 momentum

  Ultragenyx UK

  TA overlap score 40

• Peer + 0 momentum

  Chongqing Precision Biotech

  TA overlap score 40

• Peer + 0 momentum

  Eli Lilly and

  TA overlap score 40

• Peer + 0 momentum

  Teva Pharma

  TA overlap score 40

• Peer + 0 momentum

  First People's Hospital

  TA overlap score 40

Recent activity

Latest pipeline, patent, and corporate events for Novartis India.

1. Jun 8, 2026 Clinical update

   CAIN457H1301 — Phase 3

2. Jun 8, 2026 Clinical update

   CVAY736B2201 — Phase 3

3. Jun 8, 2026 Clinical update

   CTNO155X2101 — Phase 1

4. Jun 8, 2026 Clinical update

   CIDH305X2101 — Phase 1

5. Jun 8, 2026 Clinical update

   CIAG933A12101 — Phase 1

View all clinical trial activity →

• What is Novartis India?

  Novartis Pharmaceuticals is a pharma organization headquartered in CN. Primary therapeutic focus areas include Chronic Spontaneous Urticaria, Asthma, Systemic Lupus Erythematosus, Breast Cancer, Multiple Sclerosis. NovaPharmaNews links 341 clinical program(s), 47 drug profile(s),

• Is Novartis India publicly traded?

  Novartis India appears in our database through regulatory marketing authorisation or clinical trial sponsor records; a US listed ticker is not shown for this entity.

• What drugs does Novartis India develop or market?

  We link 317 drug profile(s) where Novartis India is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/novartis-ophthalmics-europe#company-drugs.

• What are the latest developments for Novartis India?

  In the last 12 months our linked public records show 341 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does Novartis India focus on?

  Novartis India focuses on Chronic Spontaneous Urticaria, Asthma, Systemic Lupus Erythematosus based on our analysis of their pipeline programs and drug development activities.